Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengzhou Univ. Skp2 compound 14i: sourced facts only. name: "Among them, compound 14i shows potent activity against the Skp2-Cks1 interaction with an IC50 value of 2.8 μM and against PC-3 and MGC-803 cells with IC50 values of 4.8 and 7.0 μM, respectively." [PMID:37204466]; target: "Among them, compound 14i shows potent activity against the Skp2-Cks1 interaction with an IC50 value of 2.8 μM and against PC-3 and MGC-803 cells with IC50 values of 4.8 and 7.0 μM, respectively." [PMID:37204466]; developer: "Key Laboratory of Technology of Drug Preparation (Zhengzhou University), Ministry of Education of China; Key Laboratory of Henan Province for Drug Quality and Evaluation; Institute of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China." [PMID:37204466]; stage: "Most importantly, compound 14i exhibited effectively anticancer effects on PC-3 and MGC-803 xenograft mice models without obvious toxicity." [PMID:37204466]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhengzhou Univ. Skp2 compound 14i.